Inhibiting insulin and mTOR signaling by afatinib and crizotinib combination fosters broad cytotoxic effects in cutaneous malignant melanoma

Lignende værker

• Combining ERBB family and MET inhibitors is an effective therapeutic strategy in cutaneous malignant melanoma independent of BRAF/NRAS mutation status
  af: Das, Ishani, et al.
  Udgivet: (2019)
• Myelination and mTOR
  af: Figlia, Gianluca, et al.
  Udgivet: (2017)
• Presence of immune cells, low tumor proliferation and wild type BRAF mutation status is associated with a favourable clinical outcome in stage III cutaneous melanoma
  af: Falkenius, Johan, et al.
  Udgivet: (2017)
• Combinational therapy of crizotinib and afatinib for malignant pleural mesothelioma
  af: Huang, Liyan, et al.
  Udgivet: (2017)
• AXL and CAV-1 play a role for MTH1 inhibitor TH1579 sensitivity in cutaneous malignant melanoma
  af: Das, Ishani, et al.
  Udgivet: (2020)